Pyxis Oncology Inc expected to post a loss of 35 cents a share - Earnings Preview
Pyxis Oncology Inc <PYXS.OQ> expected to post a loss of 35 cents a share - Earnings Preview
Pyxis Oncology Inc PYXS.OQ PYXS.O is expected to show a fall in quarterly revenue when it reports results on August 12 (estimated) for the period ending June 30 2026
The Boston Massachusetts-based company is expected to report a 99.2% decrease in revenue to $21.88 thousand from $2.82 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Pyxis Oncology Inc is for a loss of 35 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Pyxis Oncology Inc is $7.00, about 87.7% above its last closing price of $3.73
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.36 | -0.37 | -0.37 | Met | -0.3 |
Dec. 31 2026 | -0.33 | -0.34 | -0.29 | Beat | 13.9 |
Sep. 30 2025 | -0.34 | -0.34 | -0.35 | Missed | -3.4 |
Jun. 30 2025 | -0.35 | -0.35 | -0.30 | Beat | 14.7 |
Mar. 31 2025 | -0.29 | -0.29 | -0.35 | Missed | -19 |
Dec. 31 2024 | -0.34 | -0.33 | -0.25 | Beat | 24.2 |
Sep. 30 2024 | -0.31 | -0.31 | -0.35 | Missed | -11.7 |
Jun. 30 2024 | -0.32 | -0.32 | -0.29 | Beat | 10.6 |
This summary was machine generated August 10 at 11:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)